AI Bio Platform HITS Closes KRW 18.3 Billion Series B Round
Nine institutions participated, led by Premier Partners
Total funding raised reaches KRW 28.6 billion
HITS, an artificial intelligence (AI) bio platform company, announced on the 15th that it had completed a Series B funding round worth KRW 18.3 billion. The funding brings HITS' total capital raised to KRW 28.6 billion.
Premier Partners led the round, joined by six new institutional investors, including Yuanta Investment, Samsung Securities, BSK Investment, TBT Partners, and IBK Venture Investment. Three existing investors that have supported the company since its seed stage - Korea Investment Partners, Capstone Partners, and Laplace Partners - also made follow-on investments.
HITS has grown through a business model that provides core AI research platforms not only for new drug research but also for pharmaceutical companies and research institutions that analyze biological data. This has enabled the company to minimize risks from uncertainties specific to the bio industry, such as clinical trial failures and delays in obtaining regulatory approvals needed for overseas expansion, while establishing a revenue model in which stable sales accumulate in proportion to the number of customers.
HITS' flagship platform, HyperLab, is currently available on a paid basis to major domestic pharmaceutical companies and leading pharmaceutical and research institutions in Korea and abroad. In particular, it has demonstrated its technological excellence in the global market by successively signing contracts with leading cancer research institutions in Korea and North America. The company has also earned recognition for its technological capabilities, including being selected as the commercializing company for K-Fold, a bio AI model, under the AI-specialized foundation model project led by the Ministry of Science and ICT.
Using this investment as a springboard, HITS plans to complete its business transformation into an agentic AI company by the end of this year. In the first phase, through the first half of 2027, it will advance its core technologies and product portfolio, with Science AI at the center. In Korea, the company will actively target demand from pharmaceutical and biotech companies for AI transformation (AX) in research and development, drawing on its public-sector track record. In overseas markets, it will focus on acquiring new customers and increasing renewal rates, with the United States and Europe as its bases. Ultimately, starting in the second half of 2028, HITS aims to evolve beyond the specific field of drug development into an AI Scientist platform that supports life sciences research as a whole.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Yong-hoon, HITS' chief business officer (CBO), said, "In Korea, we will expand our customer base to include pharmaceutical and biotech companies. Overseas, we will build a repeatable international business model, using our existing customers in the United States and Europe as a foothold."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.